![Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/37ddafcd-e3e8-43da-8895-c46f4bddef9f/jah33313-fig-0001.png)
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association
![Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer | Journal for ImmunoTherapy of Cancer Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/7/1/90/F1.large.jpg)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer | Journal for ImmunoTherapy of Cancer
![HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development | British Journal of Cancer HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2014.388/MediaObjects/41416_2014_Article_BFbjc2014388_Fig1_HTML.jpg)
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development | British Journal of Cancer
![Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7a1926a2-bcf9-46c5-a600-9e1406c31400/gr1_lrg.jpg)
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
![Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study - ESMO Open Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/36cc6eed-8fc4-4c20-bf17-631a3fba00c4/gr2_lrg.jpg)
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study - ESMO Open
![Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer - Annals of Oncology Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3939bb25-73dd-487a-8490-1dae0e8d6902/gr1.jpg)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer - Annals of Oncology
![Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab - Annals of Oncology Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/35323a5c-4118-46d5-8006-658a5752d450/gr1_lrg.jpg)
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab - Annals of Oncology
![Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/18a1229c-045e-4e5c-af1d-6e23a5711024/jcp29216-fig-0003-m.jpg)
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library
![HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies | EMBO Molecular Medicine HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/1bc98f65-35fb-4479-a9fc-8fca4473412f/emmm201911498-fig-0003-m.jpg)
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies | EMBO Molecular Medicine
![Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e7305220-6eca-4033-a8a2-8250a401d8cd/gr2.jpg)